Northern Michigan University

NMU Commons
All NMU Master's Theses

Student Works

2013

THE ROLE OF NT1 RECEPTOR AGONISM IN DISCRIMINATIVE
STIMULUS PROPERTIES OF A D1 OR D2 DOPAMINE RECEPTOR
AGONIST
Kristoffer R. Rusch
Northern Michigan University

Follow this and additional works at: https://commons.nmu.edu/theses

Recommended Citation
Rusch, Kristoffer R., "THE ROLE OF NT1 RECEPTOR AGONISM IN DISCRIMINATIVE STIMULUS
PROPERTIES OF A D1 OR D2 DOPAMINE RECEPTOR AGONIST" (2013). All NMU Master's Theses. 494.
https://commons.nmu.edu/theses/494

This Open Access is brought to you for free and open access by the Student Works at NMU Commons. It has been
accepted for inclusion in All NMU Master's Theses by an authorized administrator of NMU Commons. For more
information, please contact kmcdonou@nmu.edu,bsarjean@nmu.edu.

THE ROLE OF NT1 RECEPTOR AGONISM IN DISCRIMINATIVE STIMULUS
PROPERTIES OF A D1 OR D2 DOPAMINE RECEPTOR AGONIST
By

Kristoffer R. Rusch

THESIS

Submitted to
Northern Michigan University
In partial fulfillment of the requirements
For the degree of

MASTER OF SCIENCE

Graduate Studies Office

2013

Assistant Provost of Graduate Education and Research

ABSTRACT
THE ROLE OF NT1 RECEPTOR AGONISM IN DISCRIMINATIVE STIMULUS
PROPERTIES OF A D1 OR D2 DOPAMINE RECEPTOR AGONIST
By
Kristoffer R. Rusch

Neurotensin is a 13 amino acid fragment of a much larger 170 amino acid
precursor protein. In the CNS, it is found co-localized with dopamine receptors in
much of the mesocorticolimbic pathway. These findings correlate with the
pathophysiology of schizophrenia in which afflicted patients display significantly
lower neurotensin in their cerebral spinal fluid and that these levels increase after
treatment by antipsychotic drugs (APD). To date, analogs of neurotensin are the only
existing agonists that can cross the blood-brain barrier and act in the CNS by binding
to NTR1 receptors. These analogs have allowed for animal testing in numerous APD
screening paradigms such as conditioned avoidance response and pre-pulse inhibition.
The results suggest that these analogs mirror atypical APD effects and avoid deficits
in cognition. This study aimed to identify the neurotensin agonist PD149163’s
relationship to the discriminate cues of groups of rats trained to discriminate either
the D1 agonist SKF81297 or the D2 agonist quinpirole from saline respectively. The
results showed that PD149163 suppressed response rates in both groups and failed to
engender generalized responding. PD149163 also failed to disrupt generalized
responding to the training drugs, suggesting that neurotensin does not mediate the
interoceptive stimulus effects that are elicited by dopamine D1 or D2 receptor
agonism.
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INTRODUCTION

1.1. Neurotensin: A brief background
Neurotensin is a neuropeptide synthesized as part of a 170 amino acid
precursor protein. This precursor remains inactive until broken down into its two
functional parts: neurotensin and neuromedin N. The active fragment of both
neuropeptides is a 13 amino acid chain differing only amongst amino acids 5-7 but
otherwise appearing identical (Carraway et al., 1973; Lambert et al., 1995). In the
peripheral nervous system, neurotensin mainly resides in the digestive system and is
released in the gut, intestines, and adrenal glands after food consumption (Ferris et
al., 1989; Kitabgi et al., 1992). As a neurotransmitter however, neurotensin is located
in a vast array of structures including dense pathways originating in the ventral
tegmental area and terminating in the nucleus accumbens, prefrontal cortex, and
amygdala (Roberts et al., 1982; Goedert et al., 1985; Kalives et al., 1984; Seroogy et
al., 1987).
1.2. Neurotensin Receptors
Once the peptide is synthesized and made active, neurotensin is then stored in
dense vesicles and released in a Ca2+-dependent manner similar to many other
neurotransmitters. When released, it may bind to one of three receptors: NTR1,
NTR2, or NTR3. The first two receptors are similar in that they both are 7
transmembrane-spanning G-Protein-coupled receptors. They differ in that the
histamine receptor antagonist levocabastine exhibits no affinity NTR1 but has an
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appreciable affinity NTR2. Neurotensin also has a significantly higher affinity for
NTR1 than for NTR2 or NTR3 (Palacios et al., 1981; Fassio et al., 2000). The third
neurotensin receptor resides intracellularly and has only a single membrane. Its role
in the neurotensin system is largely unknown (Vincent et al., 1999).
1.3. Neurotensin Receptor 1
NTR1 is often given the primary focus of neurotensin’s functional effects due
to its high neurotensin affinity binding profile. Experiments have found that NTR1
mRNA resides primarily in the ventral tegmental area, substantia nigra, medial septal
nucleus, suprachiasmatic nucleus, supramammalary area, nucleus basalis
magnocellularis, and the diagonal band of the Broca (Elde at al., 1990). Eighty to
ninety percent of dopamine neurons are found in the ventral tegmental area,
substantia nigra pars compacta, substantia nigra pars lateralis, and the retrorubal field
(Bjorklund and Lindvakk, 1984; Fallon and Loughlin, 1995) suggesting that
dopamine and neurotensin neurons have overlapping systems. Axon terminals of both
neurotensin and dopamine neurons in the midbrain also terminate in coinciding
locations in the nucleus accumbens, lateral septum, ventral medial amygdala,
prefrontal cortex, and entorhinal cortex, covering a large percentage of the
mesocorticolimbic dopamine pathway (Fallon, 1988; Febvret et al., 1991). Of the
large quantity of NTR1’s in the midbrain, 80-95% of them are located on dopamine
neurons with most of the co-localizing occurring in the VTA (Palacios and Kuhar,
1981; Uhl, 1982; Quirion 1983; Quirion et al, 1985; Herve et al, 1986; Moyse et al.,
1987; Szigethy and Beaudet, 1989; Brouard et al., 1992; Nicot et al., 1995; Fassio et
al., 2000). Electron microscope studies conducted by Dana et al. (1989) and Fassio et
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al. (2000) found that NTRs are evenly distributed over the soma and dendrites of
dopamine cells. Conversely, the dorsal striatum shows most NTR1 receptors being
located on dopamine axon terminals suggesting different functional roles in different
brain regions (Boudin et al., 1996).
As mentioned previously, NTR1 receptors have 7 transmembranes. NTR1
receptors coupled to Gq, Gs, and Gi/o proteins. The Gq subunit activation has been
identified as occurring on the c-terminal side of intracellular loop 3. Currently the
exact mechanisms of the NTR1 receptor are not known but binding sites have been
identified. Neurotensin itself seems to bind to NTR1 at transmembrane 4,
transmembrane 6, and the c-terminal side of extracellular loop 3 (Pang et al., 1998;
Barosso et al., 2000; Kitabgi, 2002). NTR1 antagonists seem to bind to
transmembrane 4, transmembrane 6, and transmembrane 7 (Labbe-Jullie et al., 1998;
Pang et al., 1998; Kitabgi, 2002). Due to the overlap of the first two binding points,
the mediation of neurotensin effects may be in part due to the level of agonist
activation at extracellular loop 3 or antagonist activation at transmembrane 7 (see
figure 1). The overall effects of intracellular activity consist of increases in calcium
release, cyclic adenosine monophosphate and arachidonic acid via their respective
alpha subunit proteins mentioned above (Wang and Wu, 1996; Skzydelski et al.,
2003). The spread of binding sites may have a place in the many differences between
the effects of NTR1 agonists. For instance, terminating transmembrane 7 binding
sites via mutations resulted in the activation of Gq protein messengers but not
activation of Gs or G i/o proteins (Hermans et al., 1996). This suggests that area
specific binding among the receptor itself could alter the effects it creates. Currently
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the release of inositol trisphosphate and subsequently calcium via the activation of Gq
at intracellular loop 3 is thought to be important for the modulation of dopamine
release by increasing the firing rate of dopamine neurons (St. Gelais et al., 2004).

Figure 1: View of NT1 receptor binding sites for both neurotensin (NT) and
neurotensin antagonists.

1.4. Schizophrenia and current antipsychotic drug treatments
Schizophrenia is a mental illness diagnosed by the presence of positive
symptoms and negative symptoms. Positive symptoms include hallucinations,
delusions, and hysteria. Negative symptoms consist of deficits in normal behavior,
including anhedonia, flat affect, or amotivation. Functional outcomes are the real life
consequences of these symptoms, such as an inability to maintain a steady job or
4

conduct normal daily-living activities. Current medications can effectively curb
positive symptoms but offer minimal gains for negative symptoms or functional
outcomes (Meltzer and McGurk 1999; Woodward et al. 2005).
One of the predominant theories of schizophrenia is that those afflicted
experience an overabundance of dopamine in their limbic system. Typical
antipsychotic drugs (APD) counter these enhanced dopamine concentrations by
blocking dopamine D2 receptors, which lessens positive symptoms. An unwanted side
effect of typical APDs is extrapyramidal side effects, in which fluid motor
movements are compromised due to the blockade of D2 receptors in the basal ganglia
(see review by Ellenbroeck, 1993).
Atypical APDs lower the risk of extrapyramidal side effects. The mechanism
of blocking D2 receptors still occurs after atypical antipsychotic drug administration,
but antagonism also occurs for other receptors, such as muscarinic, histamine H1,
serotonergic 5HT2C/2A, and adrenergic alpha1/alpha2 receptors. Due to this level of
variation it is difficult to define atypical APDs based upon a clear receptor-binding
profile, although all atypical APDs offer a lower risk for extrapyramidal side effects.
However, atypical APDs have other adverse effects, including weight gain and risk of
type II diabetes (Kroeze et al., 2003).
With schizophrenia affecting about 1% of the world’s population according to
(Regier et al., 1993) it has significant prevalence. An improvement may be found
through pursing novel mechanisms of action for atypical APDs.
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1.5. Neurotensin Expression in Schizophrenic Populations
Neurotensin became a subject of study in APD research because of its close
interactions with the dopamine system. There is currently no way of measuring
neurotensin neurotransmission in humans until more advanced neuroimaging
techniques are developed. Therefore, measures of NTR mRNA in cerebral spinal
fluid (CSF) and postmortem tissue samples were studied in schizophrenic
populations. NTR mRNA expression was significantly lower for schizophrenic
patients when compared to control groups in several clinical studies (Widerlov et al.,
1982; Lindstrom et al., 1988; Nemeroff et al., 1989). In another study by Breslin et al.
(1994) schizophrenic patients with low neurotensin mRNA in their CSF prior to APD
treatment exhibited increased neurotensin mRNA levels after chronic APD treatment.
NTR mRNA deficits in CSF of schizophrenic patients was not observed in
populations displaying anorexia/bulimia, premenstrual syndrome, and depression,
suggesting that this deficit is unique to schizophrenia (Nemeroff et al., 1989). Greater
symptom severity in schizophrenia also positively correlated with lower levels of
NTR mRNA in CSF (Garver et al., 1991). Further, observations by Sherma et al.
(1997) examined CSF of 42 patients with both schizophrenia and schizoaffective
disorder who had undergone no previous drug treatments. Patients were treated with
APDs for four weeks and a second cerebral spinal fluid sample was drawn from
compliant patients (N=18). Prior to treatment, they found that significantly more
severe symptoms were found in subjects with the lowest neurotensin in CSF. After
drug treatment, they noted that decreases in both positive and negative symptoms
correlated with higher levels of CSF.
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Postmortem studies showed no tissue variations in the amygdala of
schizophrenic patients (Biggins et al., 1983; Roberts et al. 1983; Zech et al., 1986).
Conversely, there were increased neurotensin concentrations existing in the medial
prefrontal cortex of those whom had been afflicted with schizophrenia (Manberg et
al., 1982; Nemeroff et al., 1983) and a 40% decrease of neurotensin receptor binding
in layer II of the entorhinal cortex (Wolf et al., 1995). Other variations included
reduced density of neurotensin receptor binding in caudate, cingulate, and prefrontal
cortex, in both patients on and off medication, and increased neurotensin receptor
binding in the pathway between the substantia nigra and the striatum who had been
treated with APDs (Lahti et al., 1998; Uhl and Kuhar, 1984).
1.6. Development of Neurotensin Analogs
Several neurotensin peptide analogs that could be delivered peripherally and
pass the blood-brain barrier were created with the first being a hexapeptide developed
by Eisai Ltd. (Machida et al., 1993; Tokumura et al., 1990). Eisai Hexapeptide acted
similarly to neurotensin but its affinity for neurotensin receptors was drastically lower
in humans than rats. This prompted the creation of several alternative neurotensin
analogs including PD149163, NT64L, NT66L, NT67L, NT69L, and NT77L.
PD149163 was atypical in that it may act like a pro drug, not directly binding to
neurotensin receptors until its original form had been hydrolyzed and was able to bind
(Wustrow et al., 1995). PD149163 and NT69L are currently the best researched
neurotensin analogs, but for the purposes of this study we will focus on the properties
of PD149163.
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1.7. PD149163: a unique neurotensin analog
PD149163 is different from other neurotensin analogs as it elicits its effects
with a lower affinity (~kD 159 nanomolar) for NTR1 than other neurotensin analogs
like NT69L (~kD 0.82 nanomolar) (Boules et al., 2006). It also only consists of
neurotensin’s active fragment, amino acids 8-13 (Boules et al., 2006). Despite this,
PD149163 administration increases overall cFos expression in the PFC, but not in the
striatum. cFos expression has also been raised by many dopaminergic compounds,
such as cocaine and amphetamine, suggesting a dopamine link (Petrie et al., 2004).
The neurotensin compound has also successfully blocked the startle reflex of rats
receiving both amphetamine and MK-801 in a prepulse inhibition paradigm,
mimicking the effects of previous atypical APDs (Fiefel et al., 1999, 2003, 2004;
Shilling et al., 2003). Recently, PD149163 has also been shown to inhibit conditioned
avoidance responding without inducing catalepsy, making it a strong atypical antipsychotic drug candidate (Holly et al., 2011).
1.8. Dopamine and Neurotensin Receptor Interaction
Neurotensin co-localizes with dopamine receptors. Upon neurotensin binding
to NTR1 receptors, the dimer internalizes and interacts with D2 receptors using an
allosteric binding mechanism (for review, see Maloteaux, 1998). Its interactions with
dopamine receptors at higher non-physiological doses causes a slowing and then a
halting of dopamine neuron firing, resembling the effects of APDs (Pozza et al.,
1988; Seutin et al., 1989). At lower doses there is a gradual, drawn-out depolarizing
of dopamine receptor autoinhibition -- an effect unique to neurotensin and not seen by
other dopamine neuromodulators like cholecystokinin or glutamate (Shi and Bunney,
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1990, 1991a, 1991b, 1992). D2 receptor activation causes inhibition, and thus the
induced inhibition of D2 receptors disinhibits the firing rate of dopamine neurons and
promotes dopamine release from the axon terminal. The neurotensin-induced
depolarization of dopamine receptor autoinhibitors in the VTA may contribute to the
therapeutic effects seen downstream in the mesolimbic pathway and the overall
therapeutic efficacy derived from dopamine inhibition in these areas (Myers and Lee,
1983; Pinnock and Woodruff, 1994; Seutin et al., 1989).

Figure 2: Overview of how neurotensin elicits its effects on dopamine D 2 receptors:
shows NT binding to NT1 receptors and effecting dopamine D2 receptors
allosterically. Definite effects of this interaction are summarized as a decrease in
dopaminergic D2 receptor affinity, increased levels of synaptic dopamine levels, and a
possible binding to dopamine D1 receptors on glutamatergic neurons in the prefrontal
cortex. DA:dopamine; NT: neurotensin; GLU: glutamate.

Microdialysis studies conducted by Prus et al. (2007) showed that after
neurotensin NT1 receptor agonist administration, dopamine levels increased in both
the nucleus accumbens and prefrontal cortex. It is possible that this increase in
synaptic dopamine levels may result in dopamine binding to D1 receptors on
glutamatergic neurons in the prefrontal cortex. This would explain the observed
cognitive benefits of neurotensin. In addition to an overall increase in firing rate,
9

neurotensin affects D2 receptors by reducing their ability to bind to D2 receptor
ligands (see figure 2 and table 1).

Table 1: Neurotensin’s effects on dopaminergic system at both high and low nonphysiological doses. DA:dopamine.

1.9. Drug Discrimination
Drug discrimination(DD) is a procedure in which discriminative stimuli are
used to elicit differing respective responses. The discriminative stimuli in this model
are elicited by a pharmacological agent’s effects. The most common example of this
procedure uses a rodent operant chamber equipped with two identical levers. As usual
the discriminative stimulus is a drug with the alternative being its vehicle. A subject
is then reinforced on one lever but not the other when it is under the effects of the
target drug. When vehicle is administered the other lever is reinforced but the lever
associated with the target drug is not. The frequency of responses required to achieve
reinforcement is determined by the experimenter, with common schedules of
reinforcement consisting of fixed ratio or variable interval schedules. Dependent
variables typically consist of response rate and lever-choice percentages. In the case

10

of choice models, the bulk of effort is in training the subjects to consistently
discriminate between the target drug and its vehicle.
During testing, previously unexperienced drugs are given to the trained
subjects. Lever choice determines the similarity of a novel drug’s stimulus effects to
those elicit by the training drug. You may also identify antagonistic relationships
during the testing phase by administering a training drug preceded by another
unexperienced substance. The degree by which training drug-lever responding
declines indicates that the novel drug inhibits the effects of the training drug (for
extensive review on DD covering many other applications see Glennon and Young,
2011)
Through this paradigm we know a significant amount concerning
dopaminergic drugs and their relationships to each other. The idea of two receptor
classes D2-like(D2, D3, and D4) and D1-like(D1 and D5) receptors was further
solidified in drug discrimination. In a study by Weathersby and Appel (1986), full
generalized responding occurred from the D2 receptor agonist quinpirole to the D2
receptor agonist apomorphine, but not to the D1 receptor agonist SKF38393. In
addition, the D2 receptor antagonist haloperidol attenuated quinpirole’s discriminative
cues but the D1 receptor antagonist SCH82290 did not. In other studies by Baladi et
al. (2010) quinpirole’s discriminative cue was attenuated by the D2 receptor
antagonist raclopride but not the D1 antagonist L741626. Similarly, Reavill et al.
(1993) found that the D1 receptor agonists SKF38393 and SKF83565 but not the D2
agonists PHNO or ropinirole, engendered full generalized responding to the highly
selective D1 agonist SKF81297. Furthermore, they found that SKF81297’s
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discriminative cue was attenuated by the D1 receptor agonist SCH82290, but not the
D2 receptor antagonist BRL34778.
Atypical and typical APDs have been studied using DD (for review, see Porter
and Prus, 2009). Typical APDs like haloperidol are difficult to train as discriminate
stimuli, likely due to their induced motor deficits. However, one study by McElroy et
al. (1989) managed to use haloperidol as a discriminative stimulus and showed that
generalized responding occurred to chlorpromazine, another typical APD. A more
intricate drug discrimination study performed by Prus et al. (2004) examined which
receptors mediate low doses of the atypical antipsychotic clozapine in this procedure.
They found that the muscarinic M1 receptor antagonist trihexyphenidyl, but not 5HT2A receptor antagonist M100907 or 5-HT1A receptor agonist (+)-8-OHDPAT, produced full generalized responding from a 1.25mg/kg training dose of
clozapine, but only partial generalized responding from a 5.0mg/kg training dose of
clozapine. This allows for a complex statement to be made to the degree that we may
infer that blockade of muscarinic M1 receptors mediating the discriminative stimulus
effects of low doses of clozapine. This utility is what makes drug discrimination such
a versatile tool in defining how receptor binding effects are mediated by or attenuated
to by other receptor binding effects.
In a drug discrimination study conducted by Schuck (2010), the discriminative
stimulus properties of neurotensin agonist PD149163 were examined. Ten rats were
trained to discriminate PD149163 from saline in a two lever drug discrimination
paradigm. Schuck encountered a rate suppressant effect from PD149163 at 0.50.125mg/kg dose but was able to train rats to discriminate a 0.0625mg/kg dose of
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PD149163 from vehicle in 6 of the 10 rats studied. This dose caused full generalized
responding to occur to a 0.13mg/kg dose of PD149163, but both doses significantly
reduced response rates compared to vehicle. The D2-preferring receptor antagonist
and typical APD haloperidol induced full generalized responding to PD149163 in 2 of
the 6 rats at a 0.1 mg/kg dose, but caused a significant number of session omissions
due to haloperidol’s rate-suppressant effects. This study illustrated that neurotensin
analogs like PD149163 do not only exhibit APD properties in respective drug
screening procedures mentioned before, they also elicit discriminative stimulus
effects that may be similar to those elicited by typical antipsychotic drugs.
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RATIONALE

The functional relationship between dopamine and neurotensin receptors is
currently described in terms of observed firing rates of dopaminergic neurons and
decreased affinity of dopaminergic drugs for D2 receptors after neurotensin
administration. In Schuck’s (2010) research we saw that haloperidol engendered full
generalized responding to occur from a PD149163 discriminative stimulus. However,
we do not understand if PD149163 or other neurotensin analogs elicit their effects on
the dopaminergic system through a direct binding to dopamine receptors, a cascade
effect of NTR1 binding that releases dopamine which then binds to dopamine
receptors, or some other interneuronal mechanism which does not involve
dopaminergic binding at all.
The present study trained rats to discriminate between a D1 (SKF81297) or D2
(quinpirole) receptor agonist versus saline. In order to further identify how
neurotensin and dopamine receptors shared behavioral effects, PD149163 was tested
for stimulus generalization. Combination testing was also conducted in which
PD149163 was administered before either training drug in order to determine if
NTR1 activation might inhibit the ability of either agonist to successfully bind to their
respective receptors and subsequently block their discriminative stimulus effects.

14

METHODS

2.1. Animals
This study utilized 20 male Sprague Dawley rats. Initial weights will be
assessed until all rats reach 300g. They were housed in transparent flat bottom cages
in Northern Michigan University’s rodent colony. The colony was maintained on a 12
hour light/dark cycle along with regulated temperature and humidity which remained
constant. Rats were food deprived to 85% of their free-feeding weights so that food
would motivate them to perform the drug discrimination procedure. Water was
available ad libitum in the home cages. During the daily operant procedures, rats were
fed 1-4 pellets based off their weight immediately after each daily session ended.
2.2. Pharmacological Agents
This study utilized the D1 receptor agonist SKF81297(0.15-1.2mg/kg) and D2
receptor agonist quinpirole hydrochloride (.0125-.1mg/kg) as training drugs. Stimulus
blockade tests were conducted by pretreating rats with either the D1 receptor
antagonist SCH82290 (0.001875-0.015mg/kg) or the D2 receptor antagonist
raclopride (0.2-0.8mg/kg) in conjunction with their respective agonists. Stimulus
generalization tests were conducted with the NTR1 agonist PD149163 (0.00301250.15mg/kg). Stimulus blockade tests were also conducted using PD149163. All drugs
were administered in a 1ml/kg volume. All drugs were in salt form and every drug
was dissolved in saline, which served as the vehicle in this study. Drug injections
were given 30 minutes training or testing sessions. Previous literature using similar
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discriminative stimuli was used to establish doses for training drugs quinpirole
(Weathersby and Appel, 1986) and SKF81297 (Gleason and Witkin, 2006; Reavill et
al., 1993). SCH82290 and raclopride doses were also based off of previous literature,
although raclopride could not be given at recommended dosage due to a cessation of
responding in subjects.
2.3. Apparatus
The study used 8 standard two-lever operant chambers with food magazines
that dispensed 45mg dustless grain pellets. Levers were located on the same wall as
the food magazine and were position equally from it on both sides. There was also
one 28mv house light above the left lever near the ceiling. A house fan was present
to circulate air and attenuate noise. Further noise attenuation was achieved by placing
each operant chamber into sound dulling cubicle (all acquired from Med-Associates
Inc., St. Albans, Vermont, USA). Data were recorded using MedPC version 4
software (Med-Associates Inc.).
2.4. Drug Discrimination
There were several stages to the training process in drug discrimination:
Lever press training, fixed-ratio training, errorless training, and drug discrimination
training. Test sessions were conducted after drug discrimination training was
completed.
2.4.1. Lever Press Training
As an important first step for training each rat to press a lever for food
reward, each rat was placed in an operant chamber and over the course of one hour, a
food pellet was delivered every minute. From this session, the rats learned that food is
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available in the operant chambers. After this first session, lever-press training
sessions began on the following day (note: for all of these procedures, there was only
one 15 minute session per day). During an errorless training session, only one lever
was available in the chamber (the other lever was retracted) and every lever press
resulted in the delivery of one food pellet. The lever chosen in this case was
eventually paired with the training drug’s vehicle. Each of these sessions were 45
minutes in length, or ended when a rat obtained 30 food pellets. Once a rat had
obtained 30 food pellets over two consecutive daily sessions in this phase of training,
the next phase of training (fixed ratio 30 responding) began.
2.4.2. Fixed Ratio Training
Fixed ratio 30 training (indicates that 30 lever presses will be required to
earn a single food pellet) sessions were shortened to 15 minutes from the initial 45
minutes. During the sessions, the number of lever presses necessary to earn a food
pellet was gradually increased until a rat responds 30 times to earn each food pellet.
Responding on this fixed ratio 30 reinforcement schedule must have been maintained
for 3 consecutive sessions before errorless training sessions began.
2.4.3. Errorless Training
Errorless training sessions consisted of administration of the training drug
(i.e., quinpirole 0.025mg/kg or SKF81297 0.3mg/kg) or vehicle (0.9% physiological
saline, Sigma-Aldrich, St. Louis, MO) 30 minutes prior to a session. For each rat, one
lever (left or right) was extended for drug-treatment sessions and the opposite lever
was extended for saline-treatment sessions. The drug, and saline, lever assignments
were counterbalanced between subjects. Four sessions of each condition were
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conducted in a single/double alternation design for quinpirole (Q) in the first group,
SKF81297 (K) in the second group and the discriminate vehicle saline (S) in both
groups for training sessions (i.e., QSQQSSQS, KSKKSSKS). After these sessions,
drug discrimination sessions began.
2.4.4. Drug Discrimination Training
Drug discrimination training sessions were similar to the errorless training
sessions except that both levers were extended in the operant chamber. On days when
rats were treated with quinpirole, only the quinpirole-appropriate lever resulted in the
delivery of food pellets, and on days when rats were treated with saline, only the
saline-appropriate lever resulted in the delivery of food pellets. The second group
mirrored the first with SKF81297 in the place of quinpirole. A resetting counter was
used for the fixed ratios (i.e., if a rat pressed the correct lever 10 times and then next
pressed the incorrect lever, then the rat had to press the correct lever an additional 30
times to get a food pellet). These sessions continued throughout the study. When rats
reached an accuracy of at least 80% condition-appropriate responding for 5 out of 6
consecutive sessions, then test sessions were conducted.
2.5. Testing
During a test session, a different drug was administered to the rats. If a test
drug exhibited effects similar to those produced by quinpirole or SKF81297, then rats
were expected to respond on the quinpirole or SKF81297-appropriate lever
respectively. On the other hand, if a test drug exhibited effects dissimilar to those
produced by quinpirole or SKF81297 respectively, then rats were expected to respond
on the saline-appropriate lever. A test session ended when 30 consecutive responses
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on one of the levers occurred, and no food pellet was delivered. Dependent variables
for these sessions included percentage of drug-lever responses and the number of
responses that occurred per second. Between each test session, at least one quinpirole
or SKF81297(group dependent) and one saline training session was conducted to
maintain performance accuracy.
2.6. Data Analysis
Dependent variables being measured included responses per second and drug
lever percent responding during the first successfully achieved FR30 schedule. In the
event a test session timed out percent drug lever responding was measured if 15 lever
presses or more have occurred on one lever. A one way repeated measure analysis of
variance (ANOVA) was performed to analyze response rates and percent drug-lever
responding for stimulus blockade testing, followed by a Dunnett’s multiple
comparisons test when appropriate. Percent drug-lever responding was also assessed
qualitatively, according to the following categories: full generalized responding
(>80%), partial generalized responding (60-80%), or no generalized responding
(<60%). In test sessions where stimulus blockade was being assessed the following
categories were used: full stimulus blockade (<20%), partial stimulus blockade (2040%), or no stimulus blockade (>40%). Data were expressed as means +/- the
standard error of the mean. All data analysis occurred by using Graphpad Prism for
Windows, version 5.02 (GraphPad Software, San Diego, CA).
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RESULTS

3.1. Training
The average number of training sessions till drug discrimination criteria was
met was 42.6 ± 6.4 (mean ± SEM) sessions in the group of rats trained to
discriminate SKF81297 and 26.0 ± 5.5 (mean ± SEM) sessions in the group of rats
trained to discriminate quinpirole. Out of the starting 20 rats (10 in each of the two
groups), only 6 remained in each group till the end of the study. The rats who were
eliminated passed away (N=1) or failed to learn fixed ratio training (N=1) or drug
discrimination (N=6) training criteria within 200 training sessions. PD149163 doses
were difficult to establish as a wide range of doses have been effective depending on
the task (8.0mg/kg-0.006125mg/kg) (Holly et al. 2011; Shuck, 2010). A low dose of
0.05 mg/kg was piloted and then increased until responding was no longer attainable.
In generalization testing this occurred at a dose of 0.15mg/kg. In combination
injections of PD149163 doses had to be lowered beyond .05mg/kg by half steps until
full responding could be achieved. This occurred at different times for the first group,
which was trained to discriminate SKF81297 (0.025mg/kg), and the second group,
which was trained to discriminate quinpirole (0.0125mg/kg). Due to the second
group’s first response occurring at a 0.0125mg/kg dose we had to establish several
doses below this so that there would be enough data points to establish a relationship
to VEH test sessions.
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3.2. SKF81297 Generalization
SKF81297 produced a dose response curve in which response rates following
drug injection were significantly lower (F(4,20)=7.017, P<.01) than the baseline
response rate established by VEH. The training dose (0.3mg/kg) had the highest
accuracy with a mean of 92.23% accuracy in drug-lever responding. The SKF81297
dose of 0.6mg/kg showed full generalized responding from the training dose with a
mean accuracy of 81.57%. All other doses and VEH were successfully discriminated
from the training dose. This curve yielded an ED50 of 0.2mg/kg with a 95%
confidence interval of 0.12-0.34mg/kg (see figure 3).
3.3. Quinpirole Generalization
Quinpirole produced a dose response curve in which response rates following
drug injection were not significantly different from VEH response rates. The training
dose (0.025mg/kg) had the highest mean accuracy of drug lever responding at
96.16%. The quinpirole dose of 0.05mg/kg also showed full generalized responding
from the training dose with a mean drug lever responding of 91.02%. All other doses
and VEH were successfully discriminated from the training dose. This curve yielded
an ED50 of 0.007mg/kg with a 95% confidence interval of 0.002-0.018mg/kg (see
figure 3).
3.4. PD149163 Substitution
In the group of rats trained to discriminate the D1 receptor agonist
SKF81297(0.3mg/kg) from VEH, PD149163 produced a significant decrease in
response rates at all doses tested (F(4,20)=10.27, P<0.001). This led to response
omissions at higher doses. The highest level of generalized responding occurred to a
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Figure 3: Shows a dose response curve of the D1 agonist SKF81297 (left; Group 1)
and the D2 receptor agonist quinpirole (right; Group 2). Points on graph refer to
either the mean percent of drug lever responding (top) or the mean amount of
responses made per second (bottom). VEH = saline. *P<.05, **P<.01, ***P<.001,
and ****P<.0001 versus VEH. Dashed line denotes full generalized responding.
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dose of 0.1mg/kg (32.15%), but only 2 rats responded after administration of this
dose.
In the group of rats trained to discriminate the D2 receptor agonist quinpirole
(0.025mg/kg) from VEH, PD149163 produced a significant decrease in response rates
at doses 0.05, 0.1, and 0.15mg/kg (F(4,20)=8.815, P<0.001). Motor inhibition was
observed similarly to the SKF81297 discriminating group but fewer omissions
occurred overall. The highest generalization occurred at a dose of 0.075mg/kg
(42.24%), thus representing a lack of generalized responding from the quinpirole
discriminative stimulus (see figure 4).
3.5. SCH82290+SKF81297 Stimulus Blockade Test
The D1 receptor antagonist SCH82290 at doses of 0.001875 and 0.0075mg/kg
produced significant increases in response rate compared to VEH (F(2.26,
11.3)=5.902, P<.05) when given 30 minutes prior to administration of the training
dose of D1 receptor agonist SKF81297. Full stimulus blockade occurred at doses of
0.00375, 0.0075, and 0.015mg/kg but not at a 0.001875mg/kg dose of SCH82290.
Reductions in percent drug lever responding were significantly reduced compared to
the administration of SKF81297 and the SCH23390 vehicle (F(4,20)=7.219,
P<0.0009) at doses of 0.00375, 0.0075, and 0.015. At a dose of 0.0075mg/kg,
maximum stimulus blockade occurred with 0% drug lever responding (see figure 5).
3.6. Raclopride+Quinpirole Stimulus Blockade Test
The D2 receptor antagonist raclopride did not produce a significant decrease in
response rates compared to VEH when given 30 minutes prior to the training dose of
D2 agonist quinpirole. Overall, rate suppression was observed with samples being as
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Figure 4: Shows a dose response curve of the PD149163 (left; Group 1, right; Group
2). Points on graph refer to either the mean percent of drug lever responding (top) or
the mean amount of responses made per second (bottom). VEH = saline. *P<.05,
**P<.01, ***P<.001, and ****P<.0001 versus VEH. Dashed line denotes full
generalized responding.
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Figure 5: Shows a dose response curve of D1antagonist SCH82290 preceding the D1
agonist SKF81297 .3mg/kg (left; Group 1) and the D2 antagonist raclopride
preceding D2 receptor agonist quinpirole .025mg/kg (right; Group 2). Points on graph
refer to either the mean percent of drug lever responding (top) or the mean amount of
responses made per second (bottom). VEH = saline. *P<.05, **P<.01, ***P<.001,
and ****P<.0001 versus VEH. Mean percent drug lever responses below 20%
denotes full stimulus blockade.
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low as a single rat at higher doses. Full stimulus blockade was achieved at both a 0.4
and 0.8mg/kg dose of raclopride with the mean drug percent responding at 5.88% and
3.23%, respectively. A raclopride dose of 0.2 did not create full or partial stimulus
blockade with 67.17% mean percent of drug lever responding. The statistical
significance of this decrease in mean drug lever responding percent could not be
analyzed due to insufficient data points occurring at the .4 and .8mg/kg doses (see
figure 5).
3.7. PD149163+SKF81297 Stimulus Blockade Test
PD149163 did not significantly decrease response rates compared to VEH
when given 30 minutes prior to D1 agonist SKF81297 in rats trained to discriminate
SKF81297 from VEH. PD149163 produced rate suppression which reduced the
number of subjects able to respond to discriminant cues. Of those responding, no full
or partial stimulus blockade of SKF81297 occurred. Of the rats who did respond, the
lowest mean drug lever percent (80.14%) was displayed by 4 rats at a dose of
0.05mg/kg of PD149163. No decrease in mean drug lever percent responding was
found to be statistically significant (See figure 6).
3.8. PD149163+Quinpirole Stimulus Blockade Test
PD149163 significantly reduced response rates at doses of 0.006125 and
0.0125mg/kg (F(3,5)=8.763, P=.0013) but not at a 0.0030125mg/kg dose compared
VEH when given 30 minutes prior to D2 agonist quinpirole in rats trained to
discriminate SKF81297 from VEH. Rate suppression caused omissions similar to
other PD149163 test conditions reported earlier. There was no full or partial stimulus
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Figure 6: Shows a dose response curve of PD149163 preceding the D1 agonist
SKF81297 .3mg/kg (left; Group 1) and D2 receptor agonist quinpirole .025mg/kg
(right; Group 2). Points on graph refer to either the mean percent of drug lever
responding (top) or the mean amount of responses made per second (bottom). VEH =
saline. *P<.05, **P<.01, ***P<.001, and ****P<.0001 versus VEH. Mean percent
drug lever responses below 20% denotes full stimulus blockade.
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blockade across the doses of PD149163. No decrease in mean drug lever percent
responding was found to be statistically significant (see figure 6).
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DISCUSSION

The present studied aimed to uncover the degree by which the NTR1 agonist
PD149163 generalized from or blocked the discriminative stimulus cues elicited by
D1 and D2 receptor agonists. Both the D1 receptor agonist SKF81297 and the D2
receptor agonist quinpirole were successfully established as discriminative cues,
although some animals were omitted due to failing to meet the training criteria.
Administration of SCH82290 or raclopride reduced stimulus cues of their respective
training drugs.
Weathersby and Appel (1986) used a dose of 0.025mg/kg for quinpirole as a
discriminate stimulus, reporting that any higher doses would inhibit response rates.
Once one lever training and FR30 schedules of reinforcement were achieved they
quickly met testing criteria in a mean of 26 two lever training sessions. This was
similar to what Weathersby and Appel (1986), as well as Baladi et al.(2009) who used
a slightly higher training dose of 0.032mg/kg, experienced as their training took an
average of 24 and 32 sessions respectively. The SKF81297 training dose used in the
present study was based on Reavill et al. (1993) who used doses of 0.1 and 0.2 as
discriminate stimuli but also achieved full generalized responding up to 0.4mg/kg. In
order to enhance the robustness of the discriminative stimulus effects, the present
study employed a higher dose of 0.3mg/kg. The training criteria in the present study
were met after 42.6 sessions in the SKF81297 discriminating rats, which was
consistent with other D1 agonists established as discriminate stimuli, such as
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dihydrexidine, which Gleason and Witkin (2006) reported to require 42 sessions. This
suggests that D1 agonists may be more difficult to establish as discriminate stimuli
than D2 agonists.
Eight of the twenty rats did not complete the study. With the exception of one
rat who died, these omissions occurred due to an inability to achieve 2 lever training,
FR30, or meet testing criteria within 200 sessions (more than 4 fold the average
sessions needed to meet criteria by the other 12 rats). Possible reasons for the loss of
these subjects included equipment issues or poor tolerance to training drug’s ratesuppressant effects. During testing, data omissions occurred due to rate suppressant
effects from the test compounds. These omissions were typical in rats treated high
doses of either PD149163 or raclopride. This is similar to previous APD drug
discrimination studies. Smith and Goudie (2002) were able to use the atypical APD
quetiapine as a discriminative stimulus but observed a marked suppression of
response rate compared to vehicle at the training dose. Similarly, Prus et al. (2005)
showed that rats trained to discriminate 1.25mg/kg or 5.0mg/kg displayed significant
reductions in response rates when doses increased from their training criteria to the
next highest testing dose. In unpublished data by Schuck (2010), PD149163 was
given at doses as low as 0.0625mg/kg to establish discriminative stimulus properties
and even then only 2 out of 6 of the subjects could respond.
In Schuck’s research full generalized responding occurred from PD149163 to
the typical APD haloperidol, suggesting that haloperidol may have mechanisms
similar to NRT1 receptor agonism. However, unlike haloperidol, PD149163 does not
produce catalepsy in rats which is suggestive of a novel mechanism for reduced D2
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receptor binding that mirrors haloperidol’s D2 receptor blockade (Fiefel et al., 2004;
Holly et al., 2011). This type of overlap with D2 antagonist properties has typically
been thought to have its roots in neurotensin’s ability to decrease dopamine neuron
affinity for both dopamine agonists and antagonists. This may explain a study by
Cusack et al. (2000) which showed that another neurotensin agonist NT69L prevented
haloperidol-induced catalepsy. In an extensive review of dopamine and neurotensin
interactions, Binder et al. (2001) suggested that the ability of neurotensin to decrease
dopamine agonist and antagonist affinity to D2 receptors seems to be particular to D2
receptor ligands, but does not pertain to D1 receptor ligands.
Previous explanations for this decrease in affinity to D2 receptors by D2
receptor ligands suggested that neurotensin was binding directly to dopamine
receptors, and more specifically, toD2 receptors causing a decrease in available
synapses for dopamine agonists and antagonists to bind to (Adachi et al., 1990). Prus
et al. (2007) showed that there was a significant increase in synaptic levels of
dopamine in the prefrontal cortex and nucleus accumbens after NT69L
administration, which is supportive of this notion. It is important to note that D2
receptor antagonists have readily blocked the discriminate stimulus of the D2 receptor
agonist quinpirole in other studies (Weathersby and Appel, 1986; Baladi et al., 2009).
The present study however, showed that PD149163 does not generalize or block
stimulus cues of a D1 or a D2 agonist, suggesting that it’s stimulus effects are not
derived from D1 or D2 receptor activity. This also coincides with a study done by
Nouel et al. (1992) in which changes in dopamine reuptake were measured by a
nuclear magnetic resonance spectrum before and after neurotensin was present to see
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if neurotensin’s presence might increase synaptic levels of dopamine or dopamine
reuptake. They found no significant increase in dopamine reuptake however,
suggesting that neurotensin is not directly involved in dopamine receptor binding of
any kind. This suggests that although neurotensin administration increases synaptic
dopamine levels, it does not modulate dopamine reuptake.
The rate suppressant effects of PD149163 may also be motivation related and
not strictly a sign of motor inhibition since food reinforcement was used in the
present study. Boules et al. (2000) found that the neurotensin NTR1 agonist NT69L
significantly reduced food intake and weight gain in Zucker rats, who show increased
obesity and weight gain, as well as in Sprague Dawley rats, which were used in the
present study, compared to saline treated controls. In addition, when NTR1 binding
peptides xenin and neuromedin U are administered to mice they create significant
reductions in appetite but not in NTR1 knockout mice (Kim and Mizuno, 2010). This
may be due to the fact that NTR1 binding is linked to leptin release; a hormone that
creates appetite satiation. This suggests that PD149163 may have led to appetite
suppressant effects which lowered motivation to respond for food reinforcement.
Norman et al. (2010) showed that rats performing a trace conditioning task performed
worse with administration of PD149163 than vehicle when the reinforcer consisted of
food. This contrasts with Grimond et al. (2008) who saw increases in learning with
PD149163 administration but under the effects of an aversive foot shock. This
suggests that food motivated tasks may not be effective at showing PD149163’s
behavioral effects or that aversive stimuli may be more effective at producing learned
responses.
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CONCLUSION

Overall, the present study does not NTR1-D2 receptor relationship existing
between the stimulus properties of NTR1 and D2 receptors. However, because
PD149163’s APD behavioral effects have been shown to occur at higher doses
between 1.0-8.0mg/kg it may be possible that rate suppressant effects of PD149163
may prevented a comprehensive assessment of the discriminative stimulus properties
of these compounds (Fiefel et al., 2004; Shilling and Fiefel, 2008; Holly et al., 2010).
It would be interesting to attempt a similar study using a higher affinity NTR1
receptor agonist like NT69L to see if it antagonizes D1 or D2 agonist receptor-elicited
stimulus effects. It would help to replicate this study but to precede it with a period of
chronic PD149163 administration that might allow PD149163 to build enough
tolerance that a 1.0mg/kg or higher dose may be tested for substitution or stimulus
blockade. It may also be useful to do a more thorough comparison of neurotensin
analogs (perhaps in a drug discrimination paradigm) as the complexities of the NTR1
allow for many different effects depending on the binding site and the type of Gprotein that is mediating NTR1 signaling (Binder et al., 2001; Pelaprat, 2006) of
individual compounds. Further studies using drug discrimination may include
replacing positive reinforcers with negative reinforcers like white noise or aversive
light removal to test whether PD149163 may be having appetite suppressant effects.
This would allow for a clearer depiction of PD149163’s discriminate stimulus
properties as well as its ability to substitute or attenuate those of other compounds.
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APPENDIX B

\FT60" Training
\Adam Prus Candice Schuck
S.S.1,
S1,
1":--->S2
S2,
#START:ON 7,15--->S3
S3,
60":ADD A;ON 3;SHOW 1, PELLET, A--->S4
S4,
0.1":OFF 3; IF A = 60 [@YES, @NO]
@YES:--->STOPABORTFLUSH
@NO:--->S3
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APPENDIX C

\FR1
\Written by Adam Prus 12-1-10
\Training Session
^LeftLever = 1
^RightLever = 3
^Pellet = 9
^Fan = 16
^Houselight = 15

S.S.1,
S1,
1": ON ^Fan--->S2
S2,
#START: ON ^Houselight--->S3
#K1:ON ^LEFTLEVER--->SX
#K2:ON ^RIGHTLEVER--->SX
S3,
#R1: ON ^Pellet;Add A;ADD C;Show 1, LEFT, A--->S4
#R3: ON ^Pellet;Add B;ADD C;Show 2, Right, B--->S4
S4,
0.1": OFF ^Pellet; IF C=30 [@YES,@NO]
@YES:--->STOPABORTFLUSH
@NO:--->S3
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APPENDIX D

\FR30 LEFT Training with Two Lever present. In this program, the right lever is active.
\
\
\Inputs
\1 = Left
\3 = Right
\Outputs
^LeftLever = 1
^RightLever = 3
^Pellet = 9
^Fan = 16
^Houselight = 15
\
\Variables
\A(1)=Left Lever Responses
\A(2)=Right Lever Responses
\A(3)=Reinforcers
\A(4)=Total Rate
\A(5)=Total Left Lever Rate
\A(6)=Total Right Lever Rate
\A(7)=FRR Rate
\A(8)=
\A(9)=Percent Left Lever Total Session
\A(10)=Percent Right Lever Total Session
\A(11)=Percent Left FFR
\A(12)=Percent Right FFR
\A(13)=
\A(14)=
\B(1)=FR. This is set to 1 before first pellet, equal to 2 for second pellet, etc...
\B(2)=Pellet counter. Used to increment the FR requirement if needed.
\B(3)=First choice right
\B(4)=First choice left
\B(5)=Displays 1 for left and 3 for right for the first choice
\E = INCREMENT FOR FR
DIM A = 16 \Summary data
DIM B = 16 \Variables for the program
DIM C = 100 \Total responses per reinforcer
DIM H = 100 \Left lever responses per reinforcer
DIM I = 100 \Right lever responses per reinforcer
DIM J = 100 \Total response rate (sec) per reinforcer
DIM K = 100 \Left lever rate per reinforcer
DIM L = 100 \Right lever rate per reinforcer
DIM M = 100 \Time per reinforcer 0.1" units
DIM P = 5000\Lever responses step cumulative record
\Q = incremental flag for cumulative record
\
\Z-pulses used
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\Z1 =
\Z2 =
\Z3 = Initiates pip for LeftLever reinforcement on cumulative record
\Z4 = Initiates pip for RightLever reinforcement on cumulative record
\
\Display
\1.LeftLever 2. Right Lever 3. LeftPercent 4. RightPercent 5. Time\SR+
\6.FFR_Left 7. FFR_Right 8. %FFR_Left 9. %FFR_Right 10. First_Choice
\11. Rate 12. FFR Rate 13. Blank
14. FR
15. Increment
\
\-------------------------------------------------\Investigator sets the starting FR and can increase the requirement, up to 20, everytime
\5 reinforcers are earned. K3 will set the program to FR20. No increments occur past FR20.
S.S.1,
S1,
#K1: ADD D;Show 14,FR,D--->SX
#K2: ADD E;Show 15,INC,E--->SX
#K3: SET D = 30;Show 14,FR,D--->SX
\-----------------------------------------------S.S.2, \Reinforcement schedule for left lever
S1,
1": ON ^Fan;set E=1--->S2
S2,
#Start: On ^Houselight,^LeftLever;Set B(1)=1--->S3 \B(1) used for the FFR determination
S3,
D#R1:ADD B(2),A(3);Show 5,SR+,A(3);ON ^Pellet;IF B(2)=5 [@True, @False] \B(2)=used
for incrementing the FR if needed
@True:Set B(2)=0,D=D+E--->S4
@False:--->S4
#R3:--->S3 \Resets FR counter
S4,
.05":OFF ^Pellet;ADD B(1);IF D>30 [@True, @False]
@True:Set D=30;Show 14,FR,D--->S3
@False:Show 14,FR,D--->S3
\-----------------------------------------------S.S.3, \For recording everything except the lever where the first 30 consecutive lever presses
occurred (First choice)
S1,
#R1:ADD A(1); ADD C(B(1)); ADD H(B(1)); IF B(1)=1 [@True, @False]
@True: Set A(11)=H(1)/C(1)*100;Set A(12)=I(1)/C(1)*100;Set M(B(1))=1800-Y;Set
A(7)=(H(1)+I(1))/M(1); Show 1,LeftLever,A(1);Show 2,RightLever,A(2);Show
3,Left_Percent,A(9);Show 4,Right_Percent,A(10);Show 11,Rate,A(4);Show
6,FFR_Left,H(1);Show 7,FFR_Right,I(1);Show 8,%FFR_Left,A(11);Show
9,%FFR_Right,A(12);Show 12,FFR_Rate,A(7)--->SX
@False:Set A(4)=(A(1)+A(2))/(1800-Y);Set A(9)=A(1)/(A(1)+A(2))*100;Set
A(10)=A(2)/(A(1)+A(2))*100; Show 1,LeftLever,A(1);Show 2,RightLever,A(2);Show
3,Left_Percent,A(9);Show 4,Right_Percent,A(10);Show 11,Rate,A(4)--->SX
#R3:ADD A(2); ADD C(B(1)); ADD I(B(1)); IF B(1)=1 [@True, @False] \I is for the left lever
@True: Set A(11)=H(1)/C(1)*100;Set A(12)=I(1)/C(1)*100;Set M(B(1))=1800-Y;Set
A(7)=(H(1)+I(1))/M(1);Show 1,LeftLever,A(1);Show 2,RightLever,A(2);Show
3,Left_Percent,A(9);Show 4,Right_Percent,A(10);Show 11,Rate,A(4);Show
6,FFR_Left,H(1);Show 7,FFR_Right,I(1);Show 8,%FFR_Left,A(11);Show
9,%FFR_Right,A(12);Show 12,FFR_Rate,A(7)--->SX
@False:Set A(4)=(A(1)+A(2))/(1800-Y);Set A(9)=A(1)/(A(1)+A(2))*100;Set
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A(10)=A(2)/(A(1)+A(2))*100; Show 1,LeftLever,A(1);Show 2,RightLever,A(2);Show
3,Left_Percent,A(9);Show 4,Right_Percent,A(10);Show 11,Rate,A(4)--->SX
\-----------------------------------------------S.S.4, \Session timer
S1,
#Start:Set Y=1200; Show 5,Timer,Y--->S2
S2,
1":Set Y=Y-1; Show 5,Timer,Y;IF Y=0 [@Oui,@Non]
@Oui: OFF ^RightLever,^Leftlever,^Houselight,^Fan;Show 5,SR+,A(3)-->STOPABORTFLUSH
@Non:Set A(4)=(A(1)+A(2))/(1800-Y);Show 11,Rate,A(4)--->S2
\-----------------------------------------------S.S.5, \Determines which lever the first FR was made
S1,
#R3: ADD B(3); IF B(4)>=1 [@Oui,@Non]
@Oui: Set B(3)=0,B(4)=0--->S1 \Reset the counter
@Non: IF B(3)=D [@Yes,@No]
@Yes:Set B(5)=3;Show 10,FFR,B(5)--->S2 \Lever that first FR was emitted on
@No:--->S1
#R1: ADD B(4); IF B(3)>=1 [@Oui,@Non]
@Oui: Set B(3)=0,B(4)=0--->S1 \Reset the counter
@Non: If B(4)=D [@Yes,@No]
@Yes:Set B(5)=1;Show 10,FFR,B(5)--->S2 \Lever that first FR was emitted on
@No:--->S1
S2,
0.1":--->SX
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APPENDIX E

\FR30 RIGHT Training with Two Lever present. In this program, the right lever is active.
\20 min
\Inputs
\1 = Left
\3 = Right
\Outputs
^LeftLever = 1
^RightLever = 3
^Pellet = 9
^Fan = 16
^Houselight = 15
\
\Variables
\A(1)=Left Lever Responses
\A(2)=Right Lever Responses
\A(3)=Reinforcers
\A(4)=Total Rate
\A(5)=Total Left Lever Rate
\A(6)=Total Right Lever Rate
\A(7)=FRR Rate
\A(8)=
\A(9)=Percent Left Lever Total Session
\A(10)=Percent Right Lever Total Session
\A(11)=Percent Left FFR
\A(12)=Percent Right FFR
\A(13)=
\A(14)=
\B(1)=FR. This is set to 1 before first pellet, equal to 2 for second pellet, etc...
\B(2)=Pellet counter. Used to increment the FR requirement if needed.
\B(3)=First choice right
\B(4)=First choice left
\B(5)=Displays 1 for left and 3 for right for the first choice
DIM A = 16 \Summary data
DIM B = 16 \Variables for the program
DIM C = 100 \Total responses per reinforcer
DIM H = 100 \Left lever responses per reinforcer
DIM I = 100 \Right lever responses per reinforcer
DIM J = 100 \Total response rate (sec) per reinforcer
DIM K = 100 \Left lever rate per reinforcer
DIM L = 100 \Right lever rate per reinforcer
DIM M = 100 \Time per reinforcer 0.1" units
DIM P = 5000\Lever responses step cumulative record
\Q = incremental flag for cumulative record
\
\Z-pulses used
\Z1 =
\Z2 =
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\Z3 = Initiates pip for LeftLever reinforcement on cumulative record
\Z4 = Initiates pip for RightLever reinforcement on cumulative record
\
\Display
\1.LeftLever 2. Right Lever 3. LeftPercent 4. RightPercent 5. Time\SR+
\6.FFR_Left 7. FFR_Right 8. %FFR_Left 9. %FFR_Right 10. First_Choice
\11. Rate 12. FFR Rate 13. Blank
14. FR
15. Increment
\
\-------------------------------------------------\Investigator sets the starting FR and can increase the requirement, up to 20, everytime
\5 reinforcers are earned. K3 will set the program to FR20. No increments occur past FR20.
S.S.1,
S1,
#K1: ADD D;Show 14,FR,D--->SX
#K2: ADD E;Show 15,INC,E--->SX
#K3: SET D = 30;Show 14,FR,D--->SX
\-----------------------------------------------S.S.2, \Reinforcement schedule for left lever
S1,
1": ON ^Fan;set E=1--->S2
S2,
#Start: On ^Houselight,^RightLever;Set B(1)=1--->S3 \B(1) used for the FFR determination
S3,
D#R3:ADD B(2),A(3);Show 5,SR+,A(3);ON ^Pellet;IF B(2)=5 [@True, @False] \B(2)=used
for incrementing the FR if needed
@True:Set B(2)=0,D=D+E--->S4
@False:--->S4
#R1:--->S3 \Resets FR counter
S4,
.05":OFF ^Pellet;ADD B(1);IF D>30 [@True, @False]
@True:Set D=30;Show 14,FR,D--->S3
@False:Show 14,FR,D--->S3
\-----------------------------------------------S.S.3, \For recording everything except the lever where the first 30 consecutive lever presses
occurred (First choice)
S1,
#R1:ADD A(1); ADD C(B(1)); ADD H(B(1)); IF B(1)=1 [@True, @False]
@True: Set A(11)=H(1)/C(1)*100;Set A(12)=I(1)/C(1)*100;Set M(B(1))=1200-Y;Set
A(7)=(H(1)+I(1))/M(1); Show 1,LeftLever,A(1);Show 2,RightLever,A(2);Show
3,Left_Percent,A(9);Show 4,Right_Percent,A(10);Show 11,Rate,A(4);Show
6,FFR_Left,H(1);Show 7,FFR_Right,I(1);Show 8,%FFR_Left,A(11);Show
9,%FFR_Right,A(12);Show 12,FFR_Rate,A(7)--->SX
@False:Set A(4)=(A(1)+A(2))/(1200-Y);Set A(9)=A(1)/(A(1)+A(2))*100;Set
A(10)=A(2)/(A(1)+A(2))*100; Show 1,LeftLever,A(1);Show 2,RightLever,A(2);Show
3,Left_Percent,A(9);Show 4,Right_Percent,A(10);Show 11,Rate,A(4)--->SX
#R3:ADD A(2); ADD C(B(1)); ADD I(B(1)); IF B(1)=1 [@True, @False] \I is for the left lever
@True: Set A(11)=H(1)/C(1)*100;Set A(12)=I(1)/C(1)*100;Set M(B(1))=1200-Y;Set
A(7)=(H(1)+I(1))/M(1);Show 1,LeftLever,A(1);Show 2,RightLever,A(2);Show
3,Left_Percent,A(9);Show 4,Right_Percent,A(10);Show 11,Rate,A(4);Show
6,FFR_Left,H(1);Show 7,FFR_Right,I(1);Show 8,%FFR_Left,A(11);Show
9,%FFR_Right,A(12);Show 12,FFR_Rate,A(7)--->SX
@False:Set A(4)=(A(1)+A(2))/(1200-Y);Set A(9)=A(1)/(A(1)+A(2))*100;Set
A(10)=A(2)/(A(1)+A(2))*100; Show 1,LeftLever,A(1);Show 2,RightLever,A(2);Show
3,Left_Percent,A(9);Show 4,Right_Percent,A(10);Show 11,Rate,A(4)--->SX

51

\-----------------------------------------------S.S.4, \Session timer
S1,
#Start:Set Y=1200; Show 5,Timer,Y--->S2
S2,
1":Set Y=Y-1; Show 5,Timer,Y;IF Y=0 [@Oui,@Non]
@Oui: OFF ^RightLever,^Leftlever,^Houselight,^Fan;Show 5,SR+,A(3)-->STOPABORTFLUSH
@Non:Set A(4)=(A(1)+A(2))/(1200-Y);Show 11,Rate,A(4)--->S2
\-----------------------------------------------S.S.5, \Determines which lever the first FR was made
S1,
#R3: ADD B(3); IF B(4)>=1 [@Oui,@Non]
@Oui: Set B(3)=0,B(4)=0--->S1 \Reset the counter
@Non: IF B(3)=D [@Yes,@No]
@Yes:Set B(5)=3;Show 10,FFR,B(5)--->S2 \Lever that first FR was emitted on
@No:--->S1
#R1: ADD B(4); IF B(3)>=1 [@Oui,@Non]
@Oui: Set B(3)=0,B(4)=0--->S1 \Reset the counter
@Non: If B(4)=D [@Yes,@No]
@Yes:Set B(5)=1;Show 10,FFR,B(5)--->S2 \Lever that first FR was emitted on
@No:--->S1
S2,
0.1":--->SX
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APPENDIX F

\Test session program for two lever drug discrimination. No food pellets are awarded.
\An FR20 emitted on either the left or right lever will end the session.
\
\Inputs
\1 = Left
\3 = Right
\Outputs
^LeftLever = 1
^RightLever = 3
^Pellet = 9
^Fan = 16
^Houselight = 15
\
\Variables
\A=Left Lever Presses
\B=Right Lever Presses
\C=Response Rate
\D=FFR Lever
\E=Left Percent
\F=Right Percent
\G=Left FR Counter
\H=Right FR Counter
\I=No response condition
\
\Display
\
\1. Left 2. Right 3. Rate 4. %Left
5. %Right
\6. FFR_Lever
\
S.S.1,
S1,
0.1": On ^Fan--->S2
S2,
#Start: On ^Houselight, ^LeftLever, ^RightLever--->S3
S3,
#R1:Add A, G; Set H=0; Show 1,Left,A; If G=30 [@Yes, @No]
@Yes:Set D=1;Show 6,FFR_Lever,D--->S4
@No:--->S3
#R3:Add B, H; Set G=0; Show 2,Right,B; If H=30 [@Yes, @No]
@Yes:Set D=3;Show 6,FFR_Lever,D--->S4
@No:--->S3
S4,
0.1":Set C=(A+B)/T; Set E=((A/(A+B)))*100; Set F=100-E; Show 3,Rate,C;Show
4,%Left,E;Show 5,%Right,F--->Stopabortflush
S.S.2,
S1,
#Start: Set T=0--->S2
S2,
1":ADD T; IF T=1200 [@Yes, @No]
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@Yes:set I = A+B; IF I=0 [@NORESP, @YESRESP]
@NORESP:Set C=(A+B)/T;SET E=999,F=999;Show 3,Rate,C;Show
4,%Left,E;Show 5,%Right,F--->STOPABORTFLUSH
@YESRESP:Set C=(A+B)/T; Set E=((A/(A+B)))*100; Set F=100-E; Show
3,Rate,C;Show 4,%Left,E;Show 5,%Right,F--->Stopabortflush
@No:--->S2
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APPENDIX G
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